Alector a biotech firm focused on neurodegeneration that recently signed a collaboration with GlaxoSmithKline worth up to $2.2bn, has seen its share price sink despite unveiling promising results from its lead candidate.
That reflects a broader retrenchment in neuroscience biotech stocks, which have benefitted hugely from Biogen’s Aduhelm (aducanumab) approval in June,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
